TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
China's AI Stocks Surge as Zhipu and MiniMax Hit Record Highs 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
AUSTIN, Texas, Aug. 14, 2017 -- Molecular Templates, Inc., (Nasdaq:MTEM) a clinical stage biopharmaceutical company focused on the discovery and development of Engineered Toxin Bodies (ETBs), a new class of targeted biologic therapies that possess unique mechanisms of action in oncology, today announced that Eric E. Poma, Ph.D., Chief Executive and Chief Scientific Officer, will provide a corporate overview at the 2017 Wedbush PacGrow Healthcare Conference, taking place August 15-16 at the Le Parker Meridien hotel in New York City.
| Presentation Details: | ||
| Date: | Tuesday, August 15th | |
| Time: | 2:30pm Eastern Time | |
| Location: | Le Parker Meridien Hotel, Mirus Room | |
| Webcast: | http://wsw.com/webcast/wedbush33/mtem | |
About Molecular Templates
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases. For additional information, please visit Molecular Templates’ website at www.mtem.com.
Investor Contact: Andrew McDonald, Ph.D. [email protected] 646-597-6987
